| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Ovarian Neoplasms | 63 | 2024 | 563 | 8.060 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 46 | 2024 | 364 | 6.840 |
Why?
|
| Endometrial Neoplasms | 37 | 2022 | 180 | 4.490 |
Why?
|
| Peritoneal Neoplasms | 19 | 2021 | 76 | 3.550 |
Why?
|
| Paclitaxel | 34 | 2024 | 179 | 3.050 |
Why?
|
| Uterine Cervical Neoplasms | 30 | 2022 | 276 | 3.000 |
Why?
|
| Neoplasm Recurrence, Local | 27 | 2022 | 309 | 2.610 |
Why?
|
| Fallopian Tube Neoplasms | 15 | 2021 | 49 | 2.550 |
Why?
|
| Neoplasms, Glandular and Epithelial | 15 | 2019 | 67 | 2.350 |
Why?
|
| Carboplatin | 23 | 2024 | 106 | 2.230 |
Why?
|
| Cervical Intraepithelial Neoplasia | 16 | 2015 | 80 | 2.210 |
Why?
|
| Neoplasm Staging | 51 | 2021 | 456 | 2.190 |
Why?
|
| Female | 153 | 2024 | 14421 | 2.050 |
Why?
|
| Hysterectomy | 9 | 2021 | 80 | 2.040 |
Why?
|
| Aged | 93 | 2024 | 5157 | 1.960 |
Why?
|
| Uterine Neoplasms | 7 | 2016 | 70 | 1.890 |
Why?
|
| Middle Aged | 101 | 2024 | 6796 | 1.890 |
Why?
|
| Bevacizumab | 18 | 2022 | 92 | 1.870 |
Why?
|
| Laparoscopy | 13 | 2017 | 143 | 1.790 |
Why?
|
| Carcinoma, Endometrioid | 12 | 2021 | 39 | 1.660 |
Why?
|
| Aged, 80 and over | 51 | 2024 | 1924 | 1.630 |
Why?
|
| Carcinoma | 7 | 2019 | 71 | 1.520 |
Why?
|
| Humans | 153 | 2024 | 26777 | 1.480 |
Why?
|
| Papillomavirus Infections | 15 | 2018 | 137 | 1.440 |
Why?
|
| Infusions, Parenteral | 18 | 2019 | 34 | 1.380 |
Why?
|
| Papillomaviridae | 17 | 2018 | 85 | 1.320 |
Why?
|
| Adult | 82 | 2024 | 7359 | 1.320 |
Why?
|
| Cisplatin | 18 | 2019 | 172 | 1.290 |
Why?
|
| Neoplasms, Cystic, Mucinous, and Serous | 4 | 2021 | 14 | 1.030 |
Why?
|
| Adenocarcinoma, Clear Cell | 5 | 2018 | 17 | 1.020 |
Why?
|
| Disease-Free Survival | 24 | 2022 | 225 | 1.020 |
Why?
|
| Carcinoma, Squamous Cell | 9 | 2012 | 152 | 1.010 |
Why?
|
| Laparotomy | 7 | 2017 | 29 | 1.000 |
Why?
|
| Antineoplastic Agents | 9 | 2021 | 652 | 0.960 |
Why?
|
| Colposcopy | 10 | 2016 | 61 | 0.900 |
Why?
|
| Chemotherapy, Adjuvant | 13 | 2021 | 108 | 0.880 |
Why?
|
| Carcinosarcoma | 4 | 2017 | 22 | 0.860 |
Why?
|
| Adenocarcinoma | 12 | 2021 | 284 | 0.850 |
Why?
|
| Ovariectomy | 4 | 2024 | 53 | 0.800 |
Why?
|
| Vulvar Neoplasms | 6 | 2011 | 25 | 0.760 |
Why?
|
| Cervix Uteri | 9 | 2022 | 63 | 0.760 |
Why?
|
| Prognosis | 16 | 2021 | 759 | 0.750 |
Why?
|
| Vaginal Smears | 8 | 2012 | 44 | 0.730 |
Why?
|
| Early Detection of Cancer | 7 | 2019 | 121 | 0.700 |
Why?
|
| Genital Neoplasms, Female | 7 | 2020 | 61 | 0.670 |
Why?
|
| Infusions, Intravenous | 10 | 2019 | 99 | 0.630 |
Why?
|
| Biomarkers, Tumor | 11 | 2017 | 376 | 0.630 |
Why?
|
| Survival Rate | 17 | 2021 | 407 | 0.630 |
Why?
|
| Quality of Life | 12 | 2021 | 461 | 0.620 |
Why?
|
| Lymphedema | 4 | 2020 | 13 | 0.620 |
Why?
|
| Cytoreduction Surgical Procedures | 5 | 2019 | 31 | 0.600 |
Why?
|
| Retrospective Studies | 28 | 2022 | 2426 | 0.580 |
Why?
|
| Drug Administration Schedule | 12 | 2019 | 218 | 0.550 |
Why?
|
| Sterilization, Tubal | 2 | 2015 | 6 | 0.540 |
Why?
|
| Risk Factors | 20 | 2020 | 2009 | 0.520 |
Why?
|
| Lymph Node Excision | 15 | 2020 | 94 | 0.500 |
Why?
|
| Postoperative Complications | 6 | 2020 | 605 | 0.500 |
Why?
|
| Age Factors | 8 | 2021 | 714 | 0.470 |
Why?
|
| DNA, Viral | 7 | 2015 | 50 | 0.470 |
Why?
|
| Antineoplastic Agents, Hormonal | 3 | 2021 | 25 | 0.470 |
Why?
|
| Standard of Care | 1 | 2013 | 11 | 0.460 |
Why?
|
| Sarcoma | 1 | 2014 | 28 | 0.450 |
Why?
|
| Combined Modality Therapy | 12 | 2019 | 290 | 0.440 |
Why?
|
| Catheters, Indwelling | 4 | 2017 | 19 | 0.430 |
Why?
|
| Prospective Studies | 15 | 2021 | 1216 | 0.420 |
Why?
|
| Practice Guidelines as Topic | 2 | 2012 | 233 | 0.420 |
Why?
|
| Obesity | 4 | 2015 | 648 | 0.420 |
Why?
|
| Treatment Outcome | 17 | 2021 | 2261 | 0.410 |
Why?
|
| Length of Stay | 4 | 2017 | 215 | 0.400 |
Why?
|
| Young Adult | 20 | 2018 | 2576 | 0.390 |
Why?
|
| Radiotherapy, Adjuvant | 6 | 2020 | 60 | 0.390 |
Why?
|
| Salpingectomy | 2 | 2024 | 8 | 0.390 |
Why?
|
| Lymphatic Metastasis | 13 | 2013 | 119 | 0.380 |
Why?
|
| Patient Reported Outcome Measures | 2 | 2021 | 56 | 0.360 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2012 | 160 | 0.350 |
Why?
|
| Dose-Response Relationship, Drug | 9 | 2019 | 587 | 0.350 |
Why?
|
| Sensitivity and Specificity | 13 | 2018 | 509 | 0.350 |
Why?
|
| Injections, Intraperitoneal | 4 | 2019 | 34 | 0.340 |
Why?
|
| Neoplasm Grading | 8 | 2017 | 104 | 0.340 |
Why?
|
| Cohort Studies | 9 | 2019 | 857 | 0.330 |
Why?
|
| Papanicolaou Test | 6 | 2018 | 24 | 0.330 |
Why?
|
| Follow-Up Studies | 12 | 2021 | 980 | 0.320 |
Why?
|
| Lymph Nodes | 6 | 2012 | 95 | 0.320 |
Why?
|
| Mass Screening | 5 | 2014 | 141 | 0.320 |
Why?
|
| Taxoids | 4 | 2014 | 36 | 0.320 |
Why?
|
| Disease Progression | 6 | 2021 | 450 | 0.310 |
Why?
|
| Medroxyprogesterone Acetate | 2 | 2021 | 18 | 0.310 |
Why?
|
| Clinical Trials as Topic | 5 | 2024 | 207 | 0.290 |
Why?
|
| Antibodies, Monoclonal, Humanized | 4 | 2014 | 130 | 0.290 |
Why?
|
| Logistic Models | 7 | 2015 | 399 | 0.290 |
Why?
|
| Ascites | 3 | 2015 | 19 | 0.280 |
Why?
|
| Genotype | 6 | 2015 | 441 | 0.270 |
Why?
|
| Uterine Cervical Dysplasia | 3 | 2016 | 35 | 0.270 |
Why?
|
| Carcinoma in Situ | 1 | 2006 | 44 | 0.270 |
Why?
|
| Surveys and Questionnaires | 8 | 2019 | 915 | 0.270 |
Why?
|
| Proportional Hazards Models | 7 | 2021 | 213 | 0.270 |
Why?
|
| Patient Selection | 5 | 2023 | 143 | 0.260 |
Why?
|
| Neoplasm Invasiveness | 5 | 2017 | 180 | 0.250 |
Why?
|
| Neoadjuvant Therapy | 2 | 2024 | 67 | 0.240 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2016 | 189 | 0.240 |
Why?
|
| Randomized Controlled Trials as Topic | 7 | 2017 | 357 | 0.240 |
Why?
|
| Guidelines as Topic | 1 | 2004 | 44 | 0.240 |
Why?
|
| Pasteurella Infections | 2 | 1994 | 2 | 0.240 |
Why?
|
| Mannheimia haemolytica | 2 | 1994 | 2 | 0.240 |
Why?
|
| Orosomucoid | 2 | 1994 | 4 | 0.240 |
Why?
|
| Genotyping Techniques | 2 | 2015 | 20 | 0.240 |
Why?
|
| Multicenter Studies as Topic | 4 | 2021 | 42 | 0.240 |
Why?
|
| Serum Albumin | 2 | 1994 | 35 | 0.230 |
Why?
|
| Nitriles | 1 | 2024 | 32 | 0.230 |
Why?
|
| Intraoperative Complications | 2 | 2017 | 47 | 0.230 |
Why?
|
| Pyrazoles | 1 | 2024 | 62 | 0.230 |
Why?
|
| Intestinal Obstruction | 1 | 2023 | 9 | 0.220 |
Why?
|
| Angiogenesis Inhibitors | 2 | 2021 | 104 | 0.220 |
Why?
|
| Genes, BRCA2 | 3 | 2021 | 9 | 0.220 |
Why?
|
| Genes, BRCA1 | 3 | 2021 | 11 | 0.220 |
Why?
|
| Pyrimidines | 1 | 2024 | 120 | 0.220 |
Why?
|
| Time Factors | 4 | 2024 | 1564 | 0.220 |
Why?
|
| United States | 5 | 2023 | 2030 | 0.210 |
Why?
|
| Sirolimus | 2 | 2014 | 68 | 0.210 |
Why?
|
| Cytodiagnosis | 3 | 2018 | 12 | 0.210 |
Why?
|
| Disease Management | 2 | 2021 | 84 | 0.200 |
Why?
|
| Indoles | 2 | 2022 | 97 | 0.190 |
Why?
|
| Megestrol Acetate | 2 | 2014 | 5 | 0.190 |
Why?
|
| Brachytherapy | 2 | 2013 | 46 | 0.190 |
Why?
|
| BRCA2 Protein | 1 | 2021 | 18 | 0.190 |
Why?
|
| Terminal Care | 1 | 2021 | 43 | 0.190 |
Why?
|
| BRCA1 Protein | 1 | 2021 | 23 | 0.190 |
Why?
|
| Anthropometry | 1 | 2020 | 93 | 0.180 |
Why?
|
| Drug Resistance, Neoplasm | 3 | 2021 | 145 | 0.180 |
Why?
|
| Salpingo-oophorectomy | 1 | 2019 | 2 | 0.170 |
Why?
|
| African Americans | 2 | 2021 | 350 | 0.170 |
Why?
|
| Lower Extremity | 1 | 2020 | 82 | 0.170 |
Why?
|
| Oklahoma | 4 | 2012 | 970 | 0.170 |
Why?
|
| Adolescent | 8 | 2018 | 2952 | 0.160 |
Why?
|
| Sarcoma, Endometrial Stromal | 1 | 1998 | 3 | 0.160 |
Why?
|
| Leuprolide | 1 | 1998 | 5 | 0.160 |
Why?
|
| Survival Analysis | 8 | 2019 | 277 | 0.160 |
Why?
|
| Multivariate Analysis | 3 | 2017 | 298 | 0.160 |
Why?
|
| Arrhythmias, Cardiac | 2 | 2017 | 162 | 0.150 |
Why?
|
| Pyrroles | 1 | 2018 | 35 | 0.150 |
Why?
|
| Ileus | 1 | 2017 | 7 | 0.150 |
Why?
|
| Pain Measurement | 2 | 2009 | 159 | 0.150 |
Why?
|
| Topotecan | 2 | 2010 | 12 | 0.150 |
Why?
|
| Radiotherapy | 3 | 2011 | 39 | 0.150 |
Why?
|
| Risk Assessment | 3 | 2011 | 586 | 0.150 |
Why?
|
| Oncolytic Virotherapy | 1 | 2017 | 12 | 0.150 |
Why?
|
| Ascitic Fluid | 1 | 2017 | 11 | 0.150 |
Why?
|
| Specimen Handling | 2 | 2015 | 30 | 0.140 |
Why?
|
| Cross-Sectional Studies | 2 | 2012 | 909 | 0.140 |
Why?
|
| Neoplasm, Residual | 2 | 2016 | 30 | 0.140 |
Why?
|
| Prophylactic Surgical Procedures | 1 | 2017 | 7 | 0.140 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2017 | 52 | 0.140 |
Why?
|
| Choice Behavior | 1 | 2017 | 28 | 0.140 |
Why?
|
| Toll-Like Receptor 8 | 1 | 2016 | 2 | 0.140 |
Why?
|
| Benzazepines | 1 | 2016 | 12 | 0.140 |
Why?
|
| Pneumonia | 1 | 2017 | 89 | 0.140 |
Why?
|
| Venous Thrombosis | 1 | 2017 | 98 | 0.140 |
Why?
|
| Diagnostic Imaging | 1 | 2017 | 63 | 0.140 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2017 | 72 | 0.140 |
Why?
|
| Predictive Value of Tests | 5 | 2015 | 473 | 0.140 |
Why?
|
| Maximum Tolerated Dose | 2 | 2016 | 29 | 0.130 |
Why?
|
| Immunohistochemistry | 5 | 2017 | 453 | 0.130 |
Why?
|
| Virus Integration | 1 | 2015 | 2 | 0.130 |
Why?
|
| Paraffin Embedding | 1 | 2015 | 12 | 0.130 |
Why?
|
| Biopsy | 2 | 2014 | 199 | 0.130 |
Why?
|
| Delphi Technique | 1 | 2015 | 17 | 0.130 |
Why?
|
| Triage | 2 | 2006 | 32 | 0.130 |
Why?
|
| Cyclophosphamide | 2 | 2013 | 38 | 0.130 |
Why?
|
| Gynecologic Surgical Procedures | 4 | 2020 | 33 | 0.130 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2016 | 65 | 0.130 |
Why?
|
| Consensus | 1 | 2015 | 69 | 0.120 |
Why?
|
| Immunotherapy | 1 | 2016 | 135 | 0.120 |
Why?
|
| Fallopian Tubes | 1 | 2015 | 14 | 0.120 |
Why?
|
| Sentinel Lymph Node Biopsy | 2 | 2020 | 16 | 0.120 |
Why?
|
| Sexual Behavior | 2 | 2012 | 87 | 0.120 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2016 | 139 | 0.120 |
Why?
|
| Erythromycin | 1 | 1994 | 12 | 0.120 |
Why?
|
| Antibodies, Bispecific | 1 | 2014 | 7 | 0.120 |
Why?
|
| Neoplasms, Unknown Primary | 1 | 2014 | 8 | 0.120 |
Why?
|
| Neoplasms | 1 | 2023 | 748 | 0.120 |
Why?
|
| Body Mass Index | 2 | 2014 | 384 | 0.120 |
Why?
|
| Physicians | 1 | 2015 | 80 | 0.120 |
Why?
|
| Thrombophlebitis | 1 | 2014 | 50 | 0.120 |
Why?
|
| Precancerous Conditions | 1 | 2014 | 32 | 0.120 |
Why?
|
| Recurrence | 2 | 2012 | 315 | 0.120 |
Why?
|
| Cattle Diseases | 1 | 1994 | 17 | 0.120 |
Why?
|
| Extracellular Space | 1 | 1994 | 25 | 0.120 |
Why?
|
| Vulva | 1 | 2013 | 5 | 0.110 |
Why?
|
| Feasibility Studies | 2 | 2011 | 177 | 0.110 |
Why?
|
| Urine | 1 | 2013 | 14 | 0.110 |
Why?
|
| Gastrointestinal Diseases | 1 | 2014 | 54 | 0.110 |
Why?
|
| Electrosurgery | 3 | 2012 | 15 | 0.110 |
Why?
|
| Chemoradiotherapy | 1 | 2013 | 40 | 0.110 |
Why?
|
| Surgical Wound Infection | 1 | 2014 | 104 | 0.110 |
Why?
|
| Anti-Bacterial Agents | 1 | 2017 | 496 | 0.110 |
Why?
|
| Overweight | 1 | 2014 | 110 | 0.110 |
Why?
|
| Iliac Aneurysm | 1 | 1992 | 8 | 0.110 |
Why?
|
| Genes, erbB-1 | 1 | 2012 | 2 | 0.110 |
Why?
|
| Neoplasms, Squamous Cell | 1 | 2012 | 5 | 0.100 |
Why?
|
| Quinazolines | 1 | 2012 | 31 | 0.100 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2012 | 15 | 0.100 |
Why?
|
| Ki-67 Antigen | 1 | 2012 | 23 | 0.100 |
Why?
|
| France | 1 | 2012 | 15 | 0.100 |
Why?
|
| Viral Load | 1 | 2012 | 31 | 0.100 |
Why?
|
| Membrane Proteins | 1 | 2016 | 466 | 0.100 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2012 | 21 | 0.100 |
Why?
|
| Genetic Heterogeneity | 1 | 2012 | 30 | 0.100 |
Why?
|
| Comorbidity | 2 | 2009 | 252 | 0.090 |
Why?
|
| Catheterization | 1 | 2011 | 50 | 0.090 |
Why?
|
| Odds Ratio | 3 | 2018 | 231 | 0.090 |
Why?
|
| Topoisomerase I Inhibitors | 1 | 2010 | 3 | 0.090 |
Why?
|
| Dioxoles | 1 | 2010 | 1 | 0.090 |
Why?
|
| Tetrahydroisoquinolines | 1 | 2010 | 3 | 0.090 |
Why?
|
| Abdominal Pain | 2 | 2008 | 34 | 0.090 |
Why?
|
| Neutropenia | 2 | 2017 | 34 | 0.090 |
Why?
|
| Everolimus | 2 | 2022 | 16 | 0.090 |
Why?
|
| Benzimidazoles | 2 | 2021 | 29 | 0.090 |
Why?
|
| Biomarkers | 1 | 2013 | 731 | 0.090 |
Why?
|
| Carbonic Anhydrases | 1 | 2009 | 6 | 0.090 |
Why?
|
| Catheterization, Central Venous | 2 | 2003 | 36 | 0.080 |
Why?
|
| Fever | 1 | 2009 | 30 | 0.080 |
Why?
|
| Abscess | 1 | 2009 | 24 | 0.080 |
Why?
|
| Antigens, Neoplasm | 1 | 2009 | 50 | 0.080 |
Why?
|
| Contraindications | 1 | 2009 | 13 | 0.080 |
Why?
|
| Pelvis | 5 | 2012 | 36 | 0.080 |
Why?
|
| Leg | 2 | 2020 | 131 | 0.080 |
Why?
|
| Urinary Tract Infections | 1 | 2009 | 39 | 0.080 |
Why?
|
| CA-125 Antigen | 2 | 2022 | 18 | 0.080 |
Why?
|
| Polymerase Chain Reaction | 3 | 2015 | 262 | 0.080 |
Why?
|
| Breast Neoplasms | 1 | 2014 | 441 | 0.080 |
Why?
|
| Robotics | 1 | 2009 | 42 | 0.080 |
Why?
|
| Doxorubicin | 3 | 2016 | 74 | 0.080 |
Why?
|
| Cyclosporins | 1 | 2008 | 2 | 0.080 |
Why?
|
| Fibrin Tissue Adhesive | 1 | 2008 | 5 | 0.080 |
Why?
|
| Peritoneum | 1 | 2008 | 7 | 0.080 |
Why?
|
| Patient Compliance | 1 | 2007 | 75 | 0.070 |
Why?
|
| Prevalence | 1 | 2009 | 472 | 0.070 |
Why?
|
| Antibodies, Monoclonal | 1 | 2009 | 316 | 0.070 |
Why?
|
| Algorithms | 2 | 2012 | 419 | 0.070 |
Why?
|
| Organoplatinum Compounds | 3 | 2014 | 23 | 0.070 |
Why?
|
| Mutation | 3 | 2017 | 818 | 0.070 |
Why?
|
| Reproducibility of Results | 3 | 2014 | 748 | 0.070 |
Why?
|
| Conization | 1 | 2006 | 9 | 0.070 |
Why?
|
| Catfishes | 1 | 1986 | 1 | 0.070 |
Why?
|
| Drug Residues | 1 | 1986 | 1 | 0.070 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2006 | 18 | 0.070 |
Why?
|
| Ictaluridae | 1 | 1986 | 3 | 0.070 |
Why?
|
| Contraceptive Agents, Female | 1 | 2005 | 6 | 0.070 |
Why?
|
| Gentamicins | 1 | 1986 | 15 | 0.070 |
Why?
|
| Parity | 1 | 2005 | 48 | 0.060 |
Why?
|
| Neoplasm Metastasis | 3 | 2014 | 151 | 0.060 |
Why?
|
| Kidney | 2 | 2003 | 275 | 0.060 |
Why?
|
| Double-Blind Method | 2 | 2018 | 398 | 0.060 |
Why?
|
| ErbB Receptors | 2 | 1997 | 96 | 0.060 |
Why?
|
| Injections, Intravenous | 2 | 2019 | 65 | 0.060 |
Why?
|
| Health Status | 2 | 2021 | 145 | 0.060 |
Why?
|
| Clinical Trials, Phase I as Topic | 2 | 2021 | 26 | 0.060 |
Why?
|
| Continuity of Patient Care | 1 | 2004 | 20 | 0.060 |
Why?
|
| Blotting, Western | 2 | 2016 | 503 | 0.060 |
Why?
|
| Human papillomavirus 16 | 2 | 2015 | 23 | 0.060 |
Why?
|
| Pilot Projects | 2 | 2017 | 385 | 0.060 |
Why?
|
| Cancer Vaccines | 1 | 2003 | 32 | 0.060 |
Why?
|
| Amifostine | 1 | 2003 | 5 | 0.060 |
Why?
|
| Renal Artery | 1 | 2003 | 15 | 0.060 |
Why?
|
| Ambulatory Care | 1 | 2003 | 58 | 0.060 |
Why?
|
| Gynecology | 2 | 2012 | 55 | 0.050 |
Why?
|
| Physician's Role | 1 | 2003 | 29 | 0.050 |
Why?
|
| Referral and Consultation | 2 | 2014 | 87 | 0.050 |
Why?
|
| Gene Expression Profiling | 1 | 2005 | 439 | 0.050 |
Why?
|
| Medical Oncology | 2 | 2012 | 84 | 0.050 |
Why?
|
| Cattle | 2 | 1994 | 383 | 0.050 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2017 | 662 | 0.050 |
Why?
|
| Estriol | 1 | 2022 | 3 | 0.050 |
Why?
|
| Estrone | 1 | 2022 | 5 | 0.050 |
Why?
|
| Endometrium | 1 | 2022 | 38 | 0.050 |
Why?
|
| Early Diagnosis | 1 | 2022 | 32 | 0.050 |
Why?
|
| Interleukin-12 | 1 | 2002 | 17 | 0.050 |
Why?
|
| Research Design | 1 | 2023 | 174 | 0.050 |
Why?
|
| Drug Combinations | 1 | 2022 | 50 | 0.050 |
Why?
|
| Asian Americans | 1 | 2021 | 40 | 0.050 |
Why?
|
| Reoperation | 2 | 2019 | 144 | 0.050 |
Why?
|
| ROC Curve | 2 | 2012 | 139 | 0.050 |
Why?
|
| Ovary | 1 | 2022 | 69 | 0.050 |
Why?
|
| Interleukin-10 | 1 | 2002 | 67 | 0.050 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2022 | 129 | 0.050 |
Why?
|
| Hematologic Diseases | 1 | 2021 | 10 | 0.050 |
Why?
|
| Cancer Survivors | 1 | 2021 | 37 | 0.050 |
Why?
|
| Benzamides | 1 | 2021 | 32 | 0.050 |
Why?
|
| Estradiol | 1 | 2022 | 174 | 0.050 |
Why?
|
| Dielectric Spectroscopy | 1 | 2020 | 6 | 0.050 |
Why?
|
| Time-to-Treatment | 1 | 2021 | 26 | 0.050 |
Why?
|
| Organ Size | 1 | 2020 | 83 | 0.050 |
Why?
|
| Clinical Decision-Making | 1 | 2021 | 61 | 0.050 |
Why?
|
| Pyridines | 1 | 2021 | 99 | 0.040 |
Why?
|
| Animals | 4 | 2016 | 9932 | 0.040 |
Why?
|
| Self Report | 1 | 2019 | 116 | 0.040 |
Why?
|
| Case-Control Studies | 2 | 2011 | 701 | 0.040 |
Why?
|
| Reoviridae | 1 | 2017 | 2 | 0.040 |
Why?
|
| Respiratory Tract Diseases | 1 | 2017 | 2 | 0.040 |
Why?
|
| Oncolytic Viruses | 1 | 2017 | 7 | 0.040 |
Why?
|
| Healthcare Disparities | 1 | 2018 | 78 | 0.040 |
Why?
|
| Bortezomib | 1 | 2017 | 18 | 0.040 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2002 | 801 | 0.040 |
Why?
|
| Risk Reduction Behavior | 1 | 2017 | 40 | 0.030 |
Why?
|
| Macaca fascicularis | 1 | 2016 | 45 | 0.030 |
Why?
|
| Risk | 1 | 2017 | 133 | 0.030 |
Why?
|
| Mice, SCID | 1 | 2016 | 59 | 0.030 |
Why?
|
| Mice, Inbred NOD | 1 | 2016 | 49 | 0.030 |
Why?
|
| Educational Status | 1 | 2017 | 110 | 0.030 |
Why?
|
| Hepatic Veno-Occlusive Disease | 1 | 1996 | 4 | 0.030 |
Why?
|
| Portasystemic Shunt, Surgical | 1 | 1996 | 4 | 0.030 |
Why?
|
| Perception | 1 | 2017 | 82 | 0.030 |
Why?
|
| Contrast Media | 1 | 2017 | 93 | 0.030 |
Why?
|
| Intention to Treat Analysis | 1 | 2016 | 13 | 0.030 |
Why?
|
| Laser Capture Microdissection | 1 | 2015 | 8 | 0.030 |
Why?
|
| Proctocolectomy, Restorative | 1 | 1995 | 2 | 0.030 |
Why?
|
| Molecular Typing | 1 | 2015 | 6 | 0.030 |
Why?
|
| Pelvic Neoplasms | 1 | 1995 | 8 | 0.030 |
Why?
|
| Urinary Reservoirs, Continent | 1 | 1995 | 13 | 0.030 |
Why?
|
| Comparative Genomic Hybridization | 1 | 2015 | 20 | 0.030 |
Why?
|
| Gene Dosage | 1 | 2015 | 35 | 0.030 |
Why?
|
| Postoperative Period | 1 | 2016 | 66 | 0.030 |
Why?
|
| Tumor Microenvironment | 1 | 2017 | 143 | 0.030 |
Why?
|
| Europe | 1 | 2016 | 96 | 0.030 |
Why?
|
| Polyethylene Glycols | 1 | 2016 | 93 | 0.030 |
Why?
|
| Genomic Instability | 1 | 2015 | 33 | 0.030 |
Why?
|
| Cluster Analysis | 1 | 2015 | 113 | 0.030 |
Why?
|
| Chemokines | 1 | 2016 | 73 | 0.030 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2016 | 129 | 0.030 |
Why?
|
| Stilbenes | 1 | 2016 | 90 | 0.030 |
Why?
|
| Radiography | 2 | 2008 | 200 | 0.030 |
Why?
|
| Administration, Intravenous | 1 | 2015 | 25 | 0.030 |
Why?
|
| Wnt Signaling Pathway | 1 | 2016 | 54 | 0.030 |
Why?
|
| Tumor Cells, Cultured | 1 | 2016 | 310 | 0.030 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2016 | 323 | 0.030 |
Why?
|
| Cystadenocarcinoma, Serous | 1 | 2015 | 31 | 0.030 |
Why?
|
| Male | 2 | 2023 | 12842 | 0.030 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2016 | 160 | 0.030 |
Why?
|
| Diffusion Chambers, Culture | 1 | 1994 | 6 | 0.030 |
Why?
|
| Immunodiffusion | 1 | 1994 | 12 | 0.030 |
Why?
|
| Oncogene Proteins, Viral | 1 | 2014 | 16 | 0.030 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2015 | 84 | 0.030 |
Why?
|
| Host-Pathogen Interactions | 1 | 2014 | 89 | 0.030 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2017 | 464 | 0.030 |
Why?
|
| Tamoxifen | 1 | 2014 | 30 | 0.030 |
Why?
|
| DNA Helicases | 1 | 2014 | 51 | 0.030 |
Why?
|
| Luminescent Measurements | 1 | 2013 | 30 | 0.030 |
Why?
|
| RNA, Messenger | 1 | 2016 | 645 | 0.030 |
Why?
|
| Decision Making | 1 | 2015 | 169 | 0.030 |
Why?
|
| Actuarial Analysis | 1 | 1992 | 6 | 0.030 |
Why?
|
| Body Image | 1 | 2012 | 15 | 0.030 |
Why?
|
| Protein Binding | 1 | 1994 | 631 | 0.030 |
Why?
|
| Peer Group | 1 | 2012 | 36 | 0.030 |
Why?
|
| Genetic Markers | 1 | 2012 | 92 | 0.030 |
Why?
|
| DNA Mutational Analysis | 1 | 2012 | 90 | 0.030 |
Why?
|
| Hydroxamic Acids | 1 | 2012 | 18 | 0.030 |
Why?
|
| Statistics, Nonparametric | 1 | 2012 | 80 | 0.020 |
Why?
|
| Age Distribution | 1 | 2012 | 70 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2012 | 144 | 0.020 |
Why?
|
| Ultrasonography | 1 | 1992 | 228 | 0.020 |
Why?
|
| Decision Support Techniques | 1 | 2011 | 49 | 0.020 |
Why?
|
| Tumor Burden | 1 | 2012 | 108 | 0.020 |
Why?
|
| Sulfonamides | 1 | 2012 | 68 | 0.020 |
Why?
|
| Diagnosis, Differential | 1 | 1992 | 368 | 0.020 |
Why?
|
| Dose-Response Relationship, Radiation | 1 | 2011 | 36 | 0.020 |
Why?
|
| Models, Statistical | 1 | 2011 | 118 | 0.020 |
Why?
|
| Mass Spectrometry | 1 | 2011 | 186 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2012 | 446 | 0.020 |
Why?
|
| Carbonic Anhydrase IX | 1 | 2009 | 3 | 0.020 |
Why?
|
| Immunoenzyme Techniques | 1 | 2009 | 65 | 0.020 |
Why?
|
| Karnofsky Performance Status | 1 | 2009 | 15 | 0.020 |
Why?
|
| Creatinine | 1 | 2009 | 57 | 0.020 |
Why?
|
| Sutures | 1 | 2008 | 15 | 0.020 |
Why?
|
| Weight Loss | 1 | 2009 | 72 | 0.020 |
Why?
|
| Carcinoma, Adenosquamous | 1 | 2007 | 9 | 0.020 |
Why?
|
| Medical Records | 1 | 2008 | 49 | 0.020 |
Why?
|
| Postmenopause | 1 | 2008 | 83 | 0.020 |
Why?
|
| Costs and Cost Analysis | 2 | 1999 | 39 | 0.020 |
Why?
|
| Mice | 1 | 2016 | 4396 | 0.020 |
Why?
|
| Incidence | 1 | 2008 | 546 | 0.020 |
Why?
|
| Radiation Dosage | 1 | 2006 | 53 | 0.020 |
Why?
|
| Levonorgestrel | 1 | 2005 | 5 | 0.020 |
Why?
|
| Injections, Intramuscular | 1 | 1986 | 21 | 0.020 |
Why?
|
| Injections | 1 | 2005 | 31 | 0.020 |
Why?
|
| Contraceptives, Oral | 1 | 2005 | 22 | 0.020 |
Why?
|
| Cytological Techniques | 1 | 2005 | 6 | 0.020 |
Why?
|
| Ifosfamide | 1 | 2005 | 9 | 0.020 |
Why?
|
| Abdomen | 2 | 1996 | 41 | 0.020 |
Why?
|
| Registries | 1 | 2007 | 379 | 0.020 |
Why?
|
| Preoperative Care | 1 | 2006 | 76 | 0.020 |
Why?
|
| Artifacts | 1 | 2005 | 48 | 0.020 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2005 | 189 | 0.020 |
Why?
|
| Lymphatic System | 1 | 2004 | 11 | 0.020 |
Why?
|
| Mesentery | 1 | 2004 | 9 | 0.010 |
Why?
|
| Subclavian Vein | 1 | 2003 | 4 | 0.010 |
Why?
|
| Infarction | 1 | 2003 | 8 | 0.010 |
Why?
|
| Ligation | 1 | 2003 | 40 | 0.010 |
Why?
|
| Chemoprevention | 1 | 2003 | 29 | 0.010 |
Why?
|
| Equipment Failure | 1 | 2003 | 31 | 0.010 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2003 | 23 | 0.010 |
Why?
|
| Micronutrients | 1 | 2003 | 48 | 0.010 |
Why?
|
| Uterine Cervicitis | 1 | 2002 | 1 | 0.010 |
Why?
|
| Th2 Cells | 1 | 2002 | 14 | 0.010 |
Why?
|
| Aorta, Abdominal | 1 | 2002 | 15 | 0.010 |
Why?
|
| Tumor Virus Infections | 1 | 2002 | 14 | 0.010 |
Why?
|
| Hysterectomy, Vaginal | 1 | 2001 | 4 | 0.010 |
Why?
|
| Th1 Cells | 1 | 2002 | 35 | 0.010 |
Why?
|
| Pregnancy | 1 | 2005 | 1127 | 0.010 |
Why?
|
| Radiotherapy Dosage | 1 | 2002 | 102 | 0.010 |
Why?
|
| Peptides | 1 | 2003 | 279 | 0.010 |
Why?
|
| Treatment Failure | 1 | 2001 | 68 | 0.010 |
Why?
|
| Aorta, Thoracic | 1 | 2001 | 49 | 0.010 |
Why?
|
| Jugular Veins | 1 | 1996 | 12 | 0.010 |
Why?
|
| Ileocecal Valve | 1 | 1995 | 2 | 0.010 |
Why?
|
| Urinary Catheterization | 1 | 1995 | 15 | 0.010 |
Why?
|
| Stents | 1 | 1996 | 114 | 0.010 |
Why?
|
| Patients' Rooms | 1 | 1994 | 2 | 0.010 |
Why?
|
| Operating Rooms | 1 | 1994 | 17 | 0.010 |
Why?
|